Decato, Benjamin E.
Leeming, Diana Julie
Sand, Jannie Marie Bülow
Fischer, Aryeh
Du, Shuyan
Palmer, Scott M.
Karsdal, Morten
Luo, Yi
Minnich, Anne http://orcid.org/0000-0001-5247-5276
Clinical trials referenced in this document:
Documents that mention this clinical trial
LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
https://doi.org/10.1186/s12931-022-01980-4
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
https://doi.org/10.1136/bmjresp-2021-001026
Funding for this research was provided by:
bristol myers squibb
Article History
Received: 27 July 2021
Accepted: 8 March 2022
First Online: 18 March 2022
Declarations
:
: The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. A data monitoring committee provided study oversight. All patients provided written informed consent prior to enrollment. The study protocol, amendments, and informed consent received appropriate approval by the institutional review board/independent ethics committee prior to the initiation of the study. A complete list of each institutional review board has been previously published [CitationRef removed].
: Not applicable.
: A Fischer, S Du, and Y Luo are employees of Bristol Myers Squibb and may own company stock and/or stock options. BE Decato was an employee of Bristol Myers Squibb at the time of the study. A Minnich is a consultant for Bristol Myers Squibb. SM Palmer served as Principal Investigator of the coordinating center of the previous BMS clinical trial (NCT01766817), and Duke University received research grant support to conduct that study. He has also received consulting fees from Altavant, Bristol Myers Squibb, Incyte Corporation, and Theravance Biopharma, Inc., and research grant support from Boehringer Ingleheim and Incyte Corporation. JMB Sand, DJ Leeming, and M Karsdal are employees of Nordic Bioscience and may hold company stock and/or stock options. M Karsdal and DJ Leeming are among the original inventors and patent holders for assays for PRO-C3 and C3M.